Pablo
Irimia Sieira
Consultor Médico
Vall d'Hebron Institut de Recerca
Barcelona, EspañaPublikationen in Zusammenarbeit mit Forschern von Vall d'Hebron Institut de Recerca (2)
2024
-
Long-term safety of OnabotulinumtoxinA treatment in chronic migraine patients: a five-year retrospective study
Frontiers in Neurology , Vol. 15
-
Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world
Journal of neurology, neurosurgery, and psychiatry, Vol. 95, Núm. 10, pp. 927-937